Soluble, but not transmembrane, TNF-α is required during influenza infection to limit the magnitude of immune responses and the extent of immunopathology

Journal of Immunology

Volumn 192, Issue 12, 2014, Pages 5839-5851

  De Berge, Matthew P ^a   Ely, Kenneth H ^a   Enelow, Richard I ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SOLUBLE TUMOR NECROSIS FACTOR ALPHA; TRANSMEMBRANE TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; IMMUNOPATHOLOGY; IMMUNOREGULATION; INFLUENZA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL DEATH; CELL MEMBRANE; INFLUENZA A VIRUS, H1N1 SUBTYPE; MICE; MICE, KNOCKOUT; ORTHOMYXOVIRIDAE INFECTIONS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SOLUBILITY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84902215040     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1302729     Document Type: Article

References (51)

1. Gill, J. R., Z. M. Sheng, S. F. Ely, D. G. Guinee, M. B. Beasley, J. Suh, C. Deshpande, D. J. Mollura, D. M. Morens, M. Bray, et al. 2010. Pulmonary pathologic findings of fatal 2009 pandemic influenza A/H1N1 viral infections. Arch. Pathol. Lab. Med. 134:235-243.
2. Chan, M. C., C. Y. Cheung, W. H. Chui, S. W. Tsao, J. M. Nicholls, Y. O. Chan, R. W. Chan, H. T. Long, L. L. Poon, Y. Guan, and J. S. Peiris. 2005. Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells. Respir. Res. 6:135.
3. Yu, W. C., R. W. Chan, J. Wang, E. A. Travanty, J. M. Nicholls, J. S. Peiris, R. J. Mason, and M. C. Chan. 2011. Viral replication and innate host responses in primary human alveolar epithelial cells and alveolar macrophages infected with influenza H5N1 and H1N1 viruses. J. Virol. 85:6844-6855.
4. Dienz, O., J. G. Rud, S. M. Eaton, P. A. Lanthier, E. Burg, A. Drew, J. Bunn, B. T. Suratt, L. Haynes, and M. Rincon. 2012. Essential role of IL-6 in protection against H1N1 influenza virus by promoting neutrophil survival in the lung. Mucosal Immunol. 5:258-266.
5. Miao, H., J. A. Hollenbaugh, M. S. Zand, J. Holden-Wiltse, T. R. Mosmann, A. S. Perelson, H. Wu, and D. J. Topham. 2010. Quantifying the early immune response and adaptive immune response kinetics in mice infected with influenza A virus. J. Virol. 84:6687-6698.
6. Shimomura, E., F. Suzuki, and N. Ishida. 1982. Characterization of cells infiltrating the lungs of x-irradiated and nude mice after influenza virus infection. Microbiol. Immunol. 26:129-138.
7. Wells, M. A., P. Albrecht, and F. A. Ennis. 1981. Recovery from a viral respiratory infection. I. Influenza pneumonia in normal and T-deficient mice. J. Immunol. 126:1036-1041.
8. Mauad, T., L. A. Hajjar, G. D. Callegari, L. F. Da Silva, D. Schout, F. R. Galas, V. A. Alves, D. M. Malheiros, J. O. Auler, Jr., A. F. Ferreira, et al. 2010. Lung pathology in fatal novel human influenza A (H1N1) infection. Am. J. Respir. Crit. Care Med. 181:72-79.
9. De Jong, M. D., C. P. Simmons, T. T. Thanh, V. M. Hien, G. J. Smith, T. N. Chau, D. M. Hoang, N. V. Chau, T. H. Khanh, V. C. Dong, et al. 2006. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat. Med. 12:1203-1207.
10. Tracey, K. J., H. Wei, K. R. Manogue, Y. Fong, D. G. Hesse, H. T. Nguyen, G. C. Kuo, B. Beutler, R. S. Cotran, A. Cerami, et al. 1988. Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J. Exp. Med. 167:1211-1227.
11. Tracey, K. J., Y. Fong, D. G. Hesse, K. R. Manogue, A. T. Lee, G. C. Kuo, S. F. Lowry, and A. Cerami. 1987. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330:662-664.
12. Keffer, J., L. Probert, H. Cazlaris, S. Georgopoulos, E. Kaslaris, D. Kioussis, and G. Kollias. 1991. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 10:4025-4031.
13. Peper, R. L., and H. Van Campen. 1995. Tumor necrosis factor as a mediator of inflammation in influenza A viral pneumonia. Microb. Pathog. 19:175-183.
14. Hussell, T., A. Pennycook, and P. J. Openshaw. 2001. Inhibition of tumor necrosis factor reduces the severity of virus-specific lung immunopathology. Eur. J. Immunol. 31:2566-2573.
15. Xu, L., H. Yoon, M. Q. Zhao, J. Liu, C. V. Ramana, and R. I. Enelow. 2004. Cutting edge: pulmonary immunopathology mediated by antigen-specific expression of TNF-alpha by antiviral CD8+ T cells. J. Immunol. 173:721-725.
16. De Berge, M. P., K. H. Ely, G. S. Cheng, and R. I. Enelow. 2013. ADAM17-mediated processing of TNF-a expressed by antiviral effector CD8+ T cells is required for severe T-cell-mediated lung injury. PLoS One 8:e79340.
17. Vandenabeele, P., W. Declercq, R. Beyaert, and W. Fiers. 1995. Two tumour necrosis factor receptors: structure and function. Trends Cell Biol. 5:392-399.
18. Belisle, S. E., J. R. Tisoncik, M. J. Korth, V. S. Carter, S. C. Proll, D. E. Swayne, M. Pantin-Jackwood, T. M. Tumpey, and M. G. Katze. 2010. Genomic profiling of tumor necrosis factor alpha (TNF-alpha) receptor and interleukin-1 receptor knockout mice reveals a link between TNF-alpha signaling and increased severity of 1918 pandemic influenza virus infection. J. Virol. 84:12576-12588.
19. Szretter, K. J., S. Gangappa, X. Lu, C. Smith, W. J. Shieh, S. R. Zaki, S. Sambhara, T. M. Tumpey, and J. M. Katz. 2007. Role of host cytokine responses in the pathogenesis of avian H5N1 influenza viruses in mice. J. Virol. 81:2736-2744.
20. Liu, J., M. Q. Zhao, L. Xu, C. V. Ramana, W. Declercq, P. Vandenabeele, and R. I. Enelow. 2005. Requirement for tumor necrosis factor-receptor 2 in alveolar chemokine expression depends upon the form of the ligand. Am. J. Respir. Cell Mol. Biol. 33:463-469.
21. Scheinfeld, N. 2004. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J. Dermatolog. Treat. 15:280-294.
22. Kassiotis, G., and G. Kollias. 2001. Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination. J. Exp. Med. 193:427-434.
23. Kontoyiannis, D., and G. Kollias. 2000. Accelerated autoimmunity and lupus nephritis in NZB mice with an engineered heterozygous deficiency in tumor necrosis factor. Eur. J. Immunol. 30:2038-2047.
24. Damjanovic, D., M. Divangahi, K. Kugathasan, C. L. Small, A. Zganiacz, E. G. Brown, C. M. Hogaboam, J. Gauldie, and Z. Xing. 2011. Negative regulation of lung inflammation and immunopathology by TNF-a during acute influenza infection. Am. J. Pathol. 179:2963-2976.
25. Nakamura, R., N. Maeda, K. Shibata, H. Yamada, T. Kase, and Y. Yoshikai. 2010. Interleukin-15 is critical in the pathogenesis of influenza A virus-induced acute lung injury. J. Virol. 84:5574-5582.
26. Black, R. A., C. T. Rauch, C. J. Kozlosky, J. J. Peschon, J. L. Slack, M. F. Wolfson, B. J. Castner, K. L. Stocking, P. Reddy, S. Srinivasan, et al. 1997. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385:729-733.
27. Olleros, M. L., R. Guler, N. Corazza, D. Vesin, H. P. Eugster, G. Marchal, P. Chavarot, C. Mueller, and I. Garcia. 2002. Transmembrane TNF induces an efficient cell-mediated immunity and resistance to Mycobacterium bovis bacillus Calmette-Guérin infection in the absence of secreted TNF and lymphotoxinalpha. J. Immunol. 168:3394-3401.
28. Mueller, C., N. Corazza, S. Trachsel-Løseth, H. P. Eugster, M. Bühler-Jungo, T. Brunner, and M. A. Imboden. 1999. Noncleavable transmembrane mouse tumor necrosis factor-alpha (TNFalpha) mediates effects distinct from those of wild-type TNFalpha in vitro and in vivo. J. Biol. Chem. 274:38112-38118.
29. Oikonomou, N., V. Harokopos, J. Zalevsky, C. Valavanis, A. Kotanidou, D. E. Szymkowski, G. Kollias, and V. Aidinis. 2006. Soluble TNF mediates the transition from pulmonary inflammation to fibrosis. PLoS One 1:e108.
30. Kozul, C. D., K. H. Ely, R. I. Enelow, and J. W. Hamilton. 2009. Low-dose arsenic compromises the immune response to influenza A infection in vivo. Environ. Health Perspect. 117:1441-1447.
31. Zhou, J., M. Matsuoka, H. Cantor, R. Homer, and R. I. Enelow. 2008. Cutting edge: engagement of NKG2A on CD8+ effector T cells limits immunopathology in influenza pneumonia. J. Immunol. 180:25-29.
32. Longhi, M. P., K. Wright, S. N. Lauder, M. A. Nowell, G. W. Jones, A. J. Godkin, S. A. Jones, and A. M. Gallimore. 2008. Interleukin-6 is crucial for recall of influenza-specific memory CD4 T cells. PLoS Pathog. 4:e1000006.
33. Kobasa, D., A. Takada, K. Shinya, M. Hatta, P. Halfmann, S. Theriault, H. Suzuki, H. Nishimura, K. Mitamura, N. Sugaya, et al. 2004. Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus. Nature 431:703-707.
34. Tumpey, T. M., A. García-Sastre, J. K. Taubenberger, P. Palese, D. E. Swayne, M. J. Pantin-Jackwood, S. Schultz-Cherry, A. Solórzano, N. Van Rooijen, J. M. Katz, and C. F. Basler. 2005. Pathogenicity of influenza viruses with genes from the 1918 pandemic virus: functional roles of alveolar macrophages and neutrophils in limiting virus replication and mortality in mice. J. Virol. 79:14933-14944.
35. To, K. F., P. K. Chan, K. F. Chan, W. K. Lee, W. Y. Lam, K. F. Wong, N. L. Tang, D. N. Tsang, R. Y. Sung, T. A. Buckley, et al. 2001. Pathology of fatal human infection associated with avian influenza A H5N1 virus. J. Med. Virol. 63:242-246.
36. Grell, M., H. Wajant, G. Zimmermann, and P. Scheurich. 1998. The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor. Proc. Natl. Acad. Sci. USA 95:570-575.
37. Grell, M., E. Douni, H. Wajant, M. Löhden, M. Clauss, B. Maxeiner, S. Georgopoulos, W. Lesslauer, G. Kollias, K. Pfizenmaier, and P. Scheurich. 1995. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83:793-802.
38. Müller, S., S. Rihs, J. M. Schneider, B. E. Paredes, I. Seibold, T. Brunner, and C. Mueller. 2009. Soluble TNF-alpha but not transmembrane TNF-alpha sensitizes T cells for enhanced activation-induced cell death. Eur. J. Immunol. 39:3171-3180.
39. Singh, A., and M. Suresh. 2007. A role for TNF in limiting the duration of CTL effector phase and magnitude of CD8 T cell memory. J. Leukoc. Biol. 82:1201-1211.
40. Suresh, M., A. Singh, and C. Fischer. 2005. Role of tumor necrosis factor receptors in regulating CD8 T-cell responses during acute lymphocytic choriomeningitis virus infection. J. Virol. 79:202-213.
41. Kafrouni, M. I., G. R. Brown, and D. L. Thiele. 2003. The role of TNF-TNFR2 interactions in generation of CTL responses and clearance of hepatic adenovirus infection. J. Leukoc. Biol. 74:564-571.
42. Kim, E. Y., J. J. Priatel, S. J. Teh, and H. S. Teh. 2006. TNF receptor type 2 (p75) functions as a costimulator for antigen-driven T cell responses in vivo. J. Immunol. 176:1026-1035.
43. Isogawa, M., Y. Furuichi, and F. V. Chisari. 2005. Oscillating CD8 (+) T cell effector functions after antigen recognition in the liver. Immunity 23:53-63.
44. Hufford, M. M., T. S. Kim, J. Sun, and T. J. Braciale. 2011. Antiviral CD8+ T cell effector activities in situ are regulated by target cell type. J. Exp. Med. 208:167-180.
45. Badovinac, V. P., B. B. Porter, and J. T. Harty. 2002. Programmed contraction of CD8 (+) T cells after infection. Nat. Immunol. 3:619-626.
46. Badovinac, V. P., B. B. Porter, and J. T. Harty. 2004. CD8+ T cell contraction is controlled by early inflammation. Nat. Immunol. 5:809-817.
47. Wortzman, M. E., G. H. Lin, and T. H. Watts. 2013. Intrinsic TNF/TNFR2 interactions fine-tune the CD8 T cell response to respiratory influenza virus infection in mice. PLoS One 8:e68911.
48. Sade-Feldman, M., J. Kanterman, E. Ish-Shalom, M. Elnekave, E. Horwitz, and M. Baniyash. 2013. Tumor necrosis factor-a blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation. Immunity 38:541-554.
49. Zhao, X., L. Rong, X. Zhao, X. Li, X. Liu, J. Deng, H. Wu, X. Xu, U. Erben, P. Wu, et al. 2012. TNF signaling drives myeloid-derived suppressor cell accumulation. J. Clin. Invest. 122:4094-4104.
50. Raveney, B. J., D. A. Copland, C. J. Calder, A. D. Dick, and L. B. Nicholson. 2010. TNFR1 signalling is a critical checkpoint for developing macrophages that control of T-cell proliferation. Immunology 131:340-349.
51. Chen, X., M. Bäumel, D. N. Männel, O. M. Howard, and J. J. Oppenheim. 2007. Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells. J. Immunol. 179:154-161